In vivo and ex vivo evaluation of L-type calcium channel blockers on acid beta-glucosidase in Gaucher disease mouse models.
Gaucher disease is a lysosomal storage disease caused by mutations in acid beta-glucosidase (GCase) leading to defective hydrolysis and accumulation of its substrates. Two L-type calcium channel (LTCC) blockers-verapamil and diltiazem-have been reported to modulate endoplasmic reticulum (ER) folding...
Main Authors: | Ying Sun, Benjamin Liou, Brian Quinn, Huimin Ran, You-Hai Xu, Gregory A Grabowski |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2009-10-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC2753664?pdf=render |
Similar Items
-
Isofagomine in vivo effects in a neuronopathic Gaucher disease mouse.
by: Ying Sun, et al.
Published: (2011-04-01) -
Conditional expression of human acid β-glucosidase improves the visceral phenotype in a Gaucher disease mouse model
by: Ying Sun, et al.
Published: (2006-10-01) -
Gaucher disease mouse models: point mutations at the acid β-glucosidase locus combined with low-level prosaposin expression lead to disease variants
by: Ying Sun, et al.
Published: (2005-10-01) -
Beta-blockers, left and right ventricular function, and in-vivo calcium influx in muscular dystrophy cardiomyopathy.
by: Alison Blain, et al.
Published: (2013-01-01) -
Substrate compositional variation with tissue/region and Gba1 mutations in mouse models--implications for Gaucher disease.
by: Ying Sun, et al.
Published: (2013-01-01)